Ryvu Therapeutics

Focus: Ryvu Therapeutics is a Poland-based biotechnology company focused on small molecule oncology therapeutics. The company operates as a focused mid-stage biotech with a concentrated pipeline in hematologic malignancies and solid tumors.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Ryvu Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Ryvu Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RVU120

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT04021368RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Phase 1

Help build intelligence for Ryvu Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a focused small-molecule oncology program (RVU120) with multiple Phase 2 indications including AML, myelofibrosis, and solid tumors offering diverse clinical exposure
Join a geographically differentiated biotech based in Krakow, Poland with potential cost-of-operations advantages and growing Eastern European biotech ecosystem
Contribute to a lean, specialized organization where individual impact in drug development is typically higher than in larger organizations

Watch Out For

Currently zero open job positions at the company, signaling either full capacity, hiring freeze, or early-stage headcount constraints
No Phase 3 programs in pipeline—all programs remain in Phase 1/2, meaning 5+ years minimum before potential regulatory milestones and revenue generation
Completely opaque financial position (no revenue, funding, cash, or public market data available), creating uncertainty about runway and strategic stability

Generated by Claude from Ryvu Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RVU120

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05052255RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

Phase 1/2

RVU120

Acute Myeloid Leukemia (AML)

Phase 2

Clinical Trials (1)

NCT06268574Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Phase 2